We are no longer accepting Actos cases.
Actos News
2011
Baum Hedlund Files Actos Bladder Cancer Lawsuits in California
Thursday, December 29, 2011
Baum Hedlund Aristei & Goldman has filed Actos bladder cancer lawsuits in Superior Court for the State of California for the County of Los Angeles against Japanese-based Takeda Pharmaceuticals and its subsidiaries on behalf of three California residents and their spouses alleging Actos caused their bladder cancer.
>> Read More
Drugmaker Takeda may Face Thousands of Actos Bladder Cancer Lawsuits
Wednesday, December 28, 2011
Asia's largest drug manufacturer Takeda Pharmaceuticals could be facing thousands of lawsuits in the United States stemming from a link between their diabetes drug Actos and bladder cancer. In June, a study showed that users of Actos, the world's highest-selling diabetes drug, were at an increased risk for developing bladder cancer. The link prompted France and Germany to pull Actos off the shelves. Actos made up roughly 27 percent of Takeda's revenue with sales of $4.8 billion last year. Takeda has not commented on how the lawsuits will affect profits or whether the company will be setting aside money for the impending litigation. Judges are deliberating where the high volume of Actos lawsuits will be consolidated.
>> Read More
Panel to Consider Consolidation of Actos Lawsuits in December
Monday, October 31, 2011
In December, a panel of federal judges will determine whether to consolidate Actos bladder cancer lawsuits before a single judge for pretrial management.In August, plaintiffs had petitioned the U.S. Judicial Panel on Multidistrict Litigation asking for the consolidation of the Actos lawsuits for pretrial management and discovery. Multidistrict litigation allows for product liability lawsuits to be coordinated under a single judge for pretrial proceedings, mainly to avoid discovery duplication.
>> Read More
What Compensations Can You Expect from Your Actos Bladder Lawsuit?
Wednesday, October 12, 2011
Dozens of people around the country have filed Actos lawsuits after they developed bladder cancer as a result of the drug use. Any person who has developed bladder cancer after using Actos for some time may be eligible to file a personal injury lawsuit.
>> Read More
Studies Confirm Actos Link to Bladder Cancer
Tuesday, September 27, 2011
In June 2010, the Food and Drug Administration (FDA) warned that the use of the diabetes drug Actos (pioglitazone) increased the risk of bladder cancer. The warning came after the analysis of a study conducted by the drug's manufacturer, Takeda Pharmaceuticals.
>> Read More
Actos Users Need to Watch out for Bladder Cancer Symptoms
Monday, September 26, 2011
According to data released by the Food and Drug Administration (FDA) in August, diabetes patients who have been using Actos over a long period or have been taking cumulative dosages of the drug need to be alert to the symptoms of bladder cancer. Analysis of this data prompted the health agency to release a safety alert, warning that the risk of bladder cancer is 40 percent greater in diabetes patients taking Actos for longer than two years.
>> Read More
Actos Advice for Diabetic Patients
Thursday, September 22, 2011
In June, the Food and Drug Administration (FDA) warned about an increased risk of bladder cancer from the long term use of pioglitazone, which is the active ingredient in the type II diabetes drug Actos. Patients taking Actos will have concerns about the health risks associated with the popular diabetes drug, and whether they should continue using the medication.
>> Read More
Studies Show an Increase in Bladder Cancer for Actos Patients
Friday, August 26, 2011
American Diabetes Association study published in Diabetes Care issue shows increased risk of bladder cancer in patients taking Actos (pioglitazone). Researchers gathered data taken from the U.S. Food and Drug Administration's (FDA) Adverse Event Reporting System (AERS) between 2004 and 2009.
>>Read More
Actos Taken Off the Shelves Due to Increased Risk of Bladder Cancer
Friday, August 26, 2011
France and Germany suspend use of Actos and drugs containing pioglitazone because study shows a significant risk of bladder cancer among patients taking pioglitazone.
>> Read More
FDA Warning on Actos
Thursday, August 25, 2011
FDA issues Actos Bladder Cancer safety alert warning that prolonged use of Actos has been linked to 40 percent increased risk of bladder cancer.
>> Read More |
